RBC Capital Markets maintained its 'Outperform' rating on Pyxis Oncology and increased its price target from $6 to $7. This adjustment reflects positive developments in the company's clinical trials, particularly for its head and neck cancer treatment, and upcoming regulatory feedback, suggesting a positive outlook for the stock.
RBC Capital Markets reiterated its 'Outperform' rating for Pyxis Oncology and raised its price target to $7 from $6. This positive revision is driven by the company's advancement in its Phase 1/2 clinical study for micvotabart pelidotin and pembrolizumab in head and neck squamous cell carcinoma, with upcoming FDA feedback on dose selection expected in Q1 2027. The initiation of the 'Headliner' Phase 3 trial in mid-2027 also contributes to the optimistic outlook. This news is a positive catalyst for PYXS, indicating analyst confidence in its pipeline and potential for future growth, which could lead to short-term upward price movement. The key opportunity for traders is the potential for continued positive momentum as clinical milestones are met and regulatory clarity emerges.